Abstract 1647P
Background
Pancreatic cancer is a highly fatal and aggressive disease due to its discouraging mortality and clinical treatment efficacy. Pancreas is composed of endocrine and exocrine parts, and the interlacing structure of them reminds us of the potential interaction between endocrine and exocrine cells in the oncogenesis and development of pancreatic cancer.
Methods
We depicted the changes of pancreatic endocrine cells in pancreatic cancer tissues by single-cell transcriptome sequencing, spatial transcriptome sequencing and multiplexed immunohistochemistry in human as well as in mouse models. After that, the interaction and sequence between pancreatic cancer oncogenesis and endocrine changes was explored in orthotopic transplantation mice and KPC mice. Finally, we proved the mechanism of the interaction between endocrine and exocrine parts of the pancreas through islet isolation, co-culture in vitro and co-injection in vivo.
Results
We found that, compared with normal pancreatic tissue, pancreatic endocrine cells displayed significantly different transcriptomic characteristics and increased interaction with exocrine part in pancreatic cancer tissues. Specifically, pancreatic polypeptide positive (PP+) cells showed a sharp increment accompanied with the progression of the cancer lesion. From an evolutionary perspective, the increased PP+ cells might be derived from the trans differentiation of α and β cells. Interestingly, in vivo and in vitro experiments proved that pancreatic cancer cells were able to induce the trans differentiation of α cells and β cells into GCG+PP+ and INS+PP+ double-positive cells, which further promoted pancreatic cancer proliferation in a paracrine-dependent manner and formed a positive feedback loop.
Conclusions
Our study systematically mapped the changes of pancreatic endocrine cells in pancreatic cancer and elucidated their relationship with pancreatic cancer oncogenesis and development. Meanwhile, we first time defined and characterized cancer-associated endocrine cells (CAE), which indicated that pancreatic endocrine cells should be an important component of pancreatic cancer microenvironment, thereby providing novel ideas for early diagnosis and targeted therapy of pancreatic cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Nature Science Foundation of China, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, China Postdoctoral Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22
1626P - A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Presenter: Anna Varghese
Session: Poster session 22
1629P - Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
Presenter: Alshaimaa Alhanafy
Session: Poster session 22
1630P - Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Presenter: Ashwini Cheryl Kanhailal
Session: Poster session 22
1631P - Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Presenter: Gabriela Fuentes
Session: Poster session 22
1632P - Organoids as tools for functional precision oncology in advanced pancreatic cancer
Presenter: Alice Boileve
Session: Poster session 22
1633P - Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Presenter: Nicolas Fraunhoffer
Session: Poster session 22